Advertisement
INCR vs SUPN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCR is a Buy and SUPN is a Buy.
INCR's Stochastic Oscillator sits in oversold zone for 15 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +3.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where INCR advanced for three days, in 150 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
INCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INCR as a result. In 90 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for INCR turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 40 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for INCR entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.129) is normal, around the industry mean (8.329). P/E Ratio (-2.757) is within average values for comparable stocks, (-1.568). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.640) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. INCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
SUPN's RSI Oscillator ascends from oversold territory
The RSI Indicator for SUPN moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 22 of the 26 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 61 cases where SUPN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on SUPN as a result. In 72 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for SUPN just turned positive on October 22, 2026. Looking at past instances where SUPN's MACD turned positive, the stock continued to rise in 37 of 51 cases over the following month. The odds of a continued upward trend are 73%.
Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where SUPN advanced for three days, in 224 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
SUPN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SUPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for SUPN entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.367) is normal, around the industry mean (8.329). P/E Ratio (-21.833) is within average values for comparable stocks, (-1.568). Projected Growth (PEG Ratio) (0.900) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (2.863) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 53 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. SUPN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
INCR | SUPN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 22 Undervalued | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 53 | |
SMR RATING 1..100 | 94 | 94 | |
PRICE GROWTH RATING 1..100 | 78 | 70 | |
P/E GROWTH RATING 1..100 | 27 | 98 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INCR's Valuation (22) in the Servicestothe Health Industry industry is in the same range as SUPN (24) in the Pharmaceuticals Other industry. This means that INCR’s stock grew similarly to SUPN’s over the last 12 months.
SUPN's Profit vs Risk Rating (53) in the Pharmaceuticals Other industry is somewhat better than the same rating for INCR (100) in the Servicestothe Health Industry industry. This means that SUPN’s stock grew somewhat faster than INCR’s over the last 12 months.
SUPN's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as INCR (94) in the Servicestothe Health Industry industry. This means that SUPN’s stock grew similarly to INCR’s over the last 12 months.
SUPN's Price Growth Rating (70) in the Pharmaceuticals Other industry is in the same range as INCR (78) in the Servicestothe Health Industry industry. This means that SUPN’s stock grew similarly to INCR’s over the last 12 months.
INCR's P/E Growth Rating (27) in the Servicestothe Health Industry industry is significantly better than the same rating for SUPN (98) in the Pharmaceuticals Other industry. This means that INCR’s stock grew significantly faster than SUPN’s over the last 12 months.
| INCR | SUPN | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 77% | 3 days ago 85% |
| Stochastic ODDS (%) | 3 days ago 79% | 3 days ago 79% |
| Momentum ODDS (%) | 3 days ago 87% | 3 days ago 74% |
| MACD ODDS (%) | 3 days ago 89% | 3 days ago 73% |
| TrendWeek ODDS (%) | 3 days ago 82% | 3 days ago 71% |
| TrendMonth ODDS (%) | 3 days ago 81% | 3 days ago 65% |
| Advances ODDS (%) | about 1 month ago 69% | 3 days ago 72% |
| Declines ODDS (%) | 3 days ago 81% | 17 days ago 64% |
| BollingerBands ODDS (%) | 3 days ago 77% | 3 days ago 82% |
| Aroon ODDS (%) | 3 days ago 79% | 3 days ago 71% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCR’s FA Score shows that 2 FA rating(s) are green while SUPN’s FA Score has 1 green FA rating(s).
- INCR’s FA Score: 2 green, 3 red.
- SUPN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCR’s TA Score shows that 4 TA indicator(s) are bullish while SUPN’s TA Score has 6 bullish TA indicator(s).
- INCR’s TA Score: 4 bullish, 4 bearish.
- SUPN’s TA Score: 6 bullish, 2 bearish.
Price Growth
INCR (@Pharmaceuticals: Generic) experienced а -9.15% price change this week, while SUPN (@Pharmaceuticals: Generic) price change was +3.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.14%. For the same industry, the average monthly price growth was -9.43%, and the average quarterly price growth was +3.28%.
Reported Earning Dates
INCR is expected to report earnings on Nov 17, 2026.
SUPN is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.14% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
INCR and
Correlation & Price change
A.I.dvisor tells us that INCR and SNDL have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INCR and SNDL's prices will move in lockstep.
| Ticker / NAME | Correlation To INCR | 1D Price Change % | ||
|---|---|---|---|---|
| INCR | 100% | -0.75% | ||
| SNDL - INCR | 25% Poorly correlated | -4.62% | ||
| TRLV - INCR | 24% Poorly correlated | -3.02% | ||
| AKAN - INCR | 24% Poorly correlated | -5.45% | ||
| CRON - INCR | 23% Poorly correlated | -1.79% | ||
| SUPN - INCR | 23% Poorly correlated | +0.19% | ||
More | ||||
SUPN and
Correlation & Price change
A.I.dvisor indicates that over the last year, SUPN has been loosely correlated with PRGO. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SUPN jumps, then PRGO could also see price increases.
| Ticker / NAME | Correlation To SUPN | 1D Price Change % | ||
|---|---|---|---|---|
| SUPN | 100% | +0.19% | ||
| PRGO - SUPN | 48% Loosely correlated | -0.75% | ||
| INDV - SUPN | 42% Loosely correlated | +0.34% | ||
| ELAN - SUPN | 33% Loosely correlated | -0.77% | ||
| ANIP - SUPN | 33% Poorly correlated | -1.59% | ||
| XERS - SUPN | 30% Poorly correlated | -0.37% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| KBWP | 138.57 | 1.25 | +0.91% |
| Invesco KBW Property & Casualty Insurance ETF (KBWP) | |||
| LTPZ | 47.51 | 0.16 | +0.34% |
| PIMCO 15+ Year US TIPS Index Exchange-Traded Fund (LTPZ) | |||
| TLTI | 43.21 | 0.10 | +0.23% |
| NEOS Enhanced Income 20+ Year Treasury Bond ETF (TLTI) | |||
| TRUF | 29.49 | -0.22 | -0.74% |
| VanEck Financials TruSector ETF (TRUF) | |||
| RUSC | 36.75 | -0.47 | -1.25% |
| Russell Investments U.S. Small Cap Equity ETF (RUSC) | |||